• Guangdong True Health signed a strategic cooperation framework agreement with General Technology Liaoning Pharmaceutical on Aug. 22, 2026.
• Partnership targets China’s three northeastern provinces, focusing on a minimally invasive oncology diagnosis and treatment system.
• Collaboration aims to scale deployment of the group’s self-developed minimally invasive oncology surgical robots across Northeast China.
• Work includes specialty service development, equipment technical services, operating leases, subject to required regulatory and reimbursement filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangdong True Health Medical Technology Development Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12297637), on August 25, 2026, and is solely responsible for the information contained therein.